Sullivan: 19 pharma in S&P500, spent $226B buying-back. HBR "Profits w/o Prosperity' Lazonick https://t.co/m4Tkn1FTYm #MAPonco16
4:46am September 24th 2016 via Hootsuite
Sullivan: Drug revenues - only rising line is Oncology, from $55B to over $80B. "The Big Short" movie: stock buybacks #MAPonco16
Sullivan: Following the money - lack of competitive pressure. Shows CAGR bubble plot. PM is 'THE major driver of ROI' #MAPonco16
4:44am September 24th 2016 via Hootsuite
Sullivan: 'In pure economic terms, value is crashing'. No way to rationally look at non-economic aspects. #MAPonco16
Sullivan: Shows chart, price per life year gained vs drug approval date. Trend line? Rising. #MAPonco16
4:42am September 24th 2016 via Hootsuite
Sullivan: #MAPonco16 Upcoming publication: "Failing patients, failing society: Critical examination of the UK's cancer drugs fund"
failing patients failing society critical examination of the uk's cancer drugs fund
4:41am September 24th 2016 via Hootsuite
Sullivan: 'natural experiment' the Cancer Drugs Fund: 16.2% pts had appropriate use; of these, 14.4% had improvement in outcomes #MAPonco16
4:40am September 24th 2016 via Hootsuite
Sullivan: In 5y, 277 randomized clinical trials: 31% designed to meet MCB ESMO threshold; only 15% actually met them #MAPonco16
4:38am September 24th 2016 via Hootsuite
Sullivan: Cancer 'exposes all the problems' since it is so expensive. 28 oncology drugs between '14 and '16. PFS 6.1 mos #MAPonco16
4:37am September 24th 2016 via Hootsuite
Comment: Non-linearity may not be a bad thing; it's the nature of discovery. #MAPonco16
4:36am September 24th 2016 via Hootsuite
Sullivan: Raising quality of research - 'it all went in to expensive kit, not one blind bit of improvement in research' #MAPonco16
4:28am September 24th 2016 via Hootsuite
Sullivan: There's a gap in policy between the baseline 'good quality' and the high-end expensive, latest tech. #MAPonco16
4:27am September 24th 2016 via Hootsuite
Comment: other cheaper tools may need to be exploited before more expensive ones implemented. Sullivan: Where's the baseline? #MAPonco16
4:26am September 24th 2016 via Hootsuite
Swanton comment: Feels money still should be spent on it; NHS Pathologist: Sees inequality w/in the NHS, sees 'massive gaps' #MAPonco16
4:25am September 24th 2016 via Hootsuite
Sullivan: Q: Should precision cancer medicine be this dominant? A: What should we spend money on then? #MAPonco16
4:21am September 24th 2016 via Hootsuite
Sullivan: Context: a mosaic of cultures, politics, demographics, economics. It 'shapes the dynamics of cancer tectonics' #MAPonco16
Sullivan: Shows slides of global inequality. OECD 2015 Health Spending (as a map). https://t.co/tRzJwM9GFb #MAPonco16
4:20am September 24th 2016 via Hootsuite
Sullivan: Siglitz - the larger the group, the less it will further its common interest. It is a narrow focus. #MAPonco16
4:18am September 24th 2016 via Hootsuite
Sullivan: PM is focused on high-income countries. "Is it just cream for the cream?" Fragile State Index: https://t.co/HlCFNzq70S #MAPonco16
4:17am September 24th 2016 via Hootsuite
RT @jsoriamd: Provocative talk by Pr Sullivan, London, on #PrecisionMedicine too much too fast too broad #MAPonco16 https://t.co/MOnuqZgN…
4:17am September 24th 2016 via Twitter Web Client
Sullivan: Shows box/whisker on cancer types, by survival. Breast ca - in India, 30% to 70% spread (!) PM won't cure deltas #MAPonco16
4:16am September 24th 2016 via Hootsuite
Sullivan: There are no linear relationships between scientific progress and cancer outcomes. The problem "we sell it as linear" #MAPonco16
4:14am September 24th 2016 via Hootsuite
Sullivan: Dominant paradigm is drug dev - 79% of all R&D spending on cancer #MAPonco16
4:13am September 24th 2016 via Hootsuite
Sullivan: Hit EU in mid-90's. Society takes time to react; many disciplines involved (Political, Regulatory, Economic, History #MAPonco16
Sullivan: Birch Bayh / Bob Dole amended patent law in 70's to allow universities to gain IP and license it out. '80 in-force #MAPonco16
4:11am September 24th 2016 via Hootsuite
Sullivan: Outline: Context; Economics; and Power. Context is everything: 1960's; public monies; 70's age of worries abt spending #MAPonco16
Sullivan: The individual and society: fundamental questions; de Tocqueville's argument - the individual's need over society's #MAPonco16
4:10am September 24th 2016 via Hootsuite
Sullivan: Cancer: 'pinnacle of the global health mountain'. 'Cancer research is the single largest research endeavor in history' #MAPonco16
4:08am September 24th 2016 via Hootsuite
Richard Sullivan (Kings College, London) Too much, too soon, too fast? #MAPonco16 Health economics.
Live-tweeting today from #MAPonco16 Program: https://t.co/GeIl6pTFA2
4:07am September 24th 2016 via Hootsuite
Ig Nobel prizes: trousers for rats and the truthfulness of liars | The Guardian https://t.co/iZ7ZGw06fp
11:30pm September 23rd 2016 via Hootsuite
Facebook Says It Gave Advertisers Inflated Video Metrics - Bloomberg https://t.co/DGC6umfuwk 3 sec = viewed? Really?!?
10:55pm September 23rd 2016 via Hootsuite
Opposition to Galileo was scientific, not just religious | Aeon Ideas https://t.co/OSwqcxdMYO
9:00pm September 23rd 2016 via Hootsuite
Ig Nobel win for Alpine 'goat man' - BBC News https://t.co/1DBCNb1sSt
8:05pm September 23rd 2016 via Hootsuite
RT @NatureNews: 8 scientists who are among the winners of the 2016 MacArthur 'genius grants' https://t.co/AmztjlaqRt https://t.co/NeMiuhhsKi
7:01pm September 23rd 2016 via Hootsuite
How the FDA Manipulates the Media - Scientific American https://t.co/pyAm9tVML4
6:10pm September 23rd 2016 via Hootsuite
Sotiriou: MINDACT study with MammaPrint '16 NEJM https://t.co/ilZCG1RF63 +/- chemo, underpowered study MAPonco16
12:48pm September 23rd 2016 via Hootsuite
Sotiriou: Optima study comparing GEP for br ca: "broadly equivalent" '16 ref https://t.co/LDNnLNPWxC #MAPonco16
12:44pm September 23rd 2016 via Hootsuite
Sotiriou: Using GHDX's Oncotype, the signature captures high proliferation, resulting in poor prognosis. #MAPonco16
12:41pm September 23rd 2016 via Hootsuite
Sotiriou: With Gene Exp Profiles (GEP) - Put together an online tool 'Adjuvant!' to help define risk https://t.co/rRce03392G #MAPonco16
12:39pm September 23rd 2016 via Hootsuite
Christos Sotiriou (Universite Libre de Bruxelles, Brussels, Belgium): Prediction of relapse #MAPonco16
12:32pm September 23rd 2016 via Hootsuite
Azria: Needing to understand mechanism, technologies needed, improve cost-effectiveness of treatment #MAPonco16
12:29pm September 23rd 2016 via Hootsuite
Azria: In '13 started a new consortium 'Requite' https://t.co/XUAhNohdcz integrate methods, increase PPV https://t.co/kyF5LyxnMy #MAPonco16
12:28pm September 23rd 2016 via Hootsuite
Azria: By using an assay called RILA, was able to show 90% sens but low specificity; working with a MALDI-TOF to increase spec #MAPonco16
12:23pm September 23rd 2016 via Hootsuite
Azria: Shows the complexity of radiotherapy's effects on the system - from this '16 ref https://t.co/U8AeegSiqz #MAPonco16
12:06pm September 23rd 2016 via Hootsuite
Azria: There are ~28.7M cancer survivors; about 50% underwent radiotherapy. Toxicity impairs QoL in survivors #MAPonco16
12:02pm September 23rd 2016 via Hootsuite
David Azria (INSERM, France): Prediction of normal tissue late effect after radiotherapy #MAPonco16
12:01pm September 23rd 2016 via Hootsuite
Easton: Genetic susceptibility - about 60% currently explained, overall for EU population #MAPonco16
11:55am September 23rd 2016 via Hootsuite
Easton: Improving prediction: more SNPs, larger studies; rare var's (WES, WGS), imaging #MAPonco16
11:54am September 23rd 2016 via Hootsuite
